Fullcircle Wealth LLC Makes New Investment in Tempest Therapeutics, Inc. (NASDAQ:TPST)

Fullcircle Wealth LLC purchased a new position in Tempest Therapeutics, Inc. (NASDAQ:TPST) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 62,000 shares of the company’s stock, valued at approximately $87,000. Fullcircle Wealth LLC owned approximately 0.28% of Tempest Therapeutics at the end of the most recent reporting period.

Separately, Dimensional Fund Advisors LP bought a new stake in Tempest Therapeutics in the 2nd quarter valued at $55,000. 22.52% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, major shareholder Versant Venture Capital Vi, L. sold 387,999 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $1.10, for a total value of $426,798.90. Following the completion of the sale, the insider now owns 209,941 shares of the company’s stock, valued at approximately $230,935.10. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 3.27% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $47.00 target price on shares of Tempest Therapeutics in a report on Thursday, October 10th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $20.75.

Tempest Therapeutics Stock Performance

Shares of TPST stock opened at $0.91 on Friday. Tempest Therapeutics, Inc. has a 12 month low of $0.88 and a 12 month high of $6.00. The company’s fifty day simple moving average is $1.24 and its 200-day simple moving average is $2.08. The firm has a market cap of $22.93 million, a PE ratio of -0.57 and a beta of -1.78. The company has a quick ratio of 2.17, a current ratio of 2.17 and a debt-to-equity ratio of 0.12.

Tempest Therapeutics (NASDAQ:TPST) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.05. Equities research analysts expect that Tempest Therapeutics, Inc. will post -1.5 EPS for the current fiscal year.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.